Peter Lu is Global Head of the Firm’s China Practice. He advises clients on their most strategic mandates, with a particular focus on corporate matters, complex restructurings and strategic litigation. Across these three core areas, Peter advises clients on cross-border M&A, joint ventures, directors’ duties, governance matters, complex restructurings, disputes, crisis management and more. He advises private, public and state-owned enterprises across a number of industries, including healthcare, financial services, media, infrastructure, consumer, energy, transportation and professional services.
Results
Transactional matters
- Advised Novartis Groupe France SAS sold the company CellforCure and its cell and gene therapy development and production site in Les Ulis, France, to Seqens SAS
- Advised Bank of China on M&A, general corporate, and restructuring matters*
- Advised ICBC on selling certain shares held by the bank*
Recognitions
- Legal 500 UK, Recommended, 2021, 2025-2026
- Global Restructuring Review GRR 30, Recommended, 2024
- Global Restructuring Review GRR 100, Recommended, 2023
Capabilities and industries
Regional markets
Community
- Law Society of England and Wales, member
Credentials
Education
- University College London, LLB
- University of York, MSc
- Nottingham University, BSc
Admissions
- England and Wales
Languages
- English
- Chinese (Mandarin)